TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: clearance of strongyloides infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Regional Cerebral Oxygen Saturations (Left and Right)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Time-matched QT Corrected by the Fridericia Formula (QTcF) Change From Baseline to Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent excess weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events, including serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of satisfaction with information received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Sleep Duration & Timing
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Dietary Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of clinical benefit (CB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of venous and/or arterial thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Number of Deaths by Suicide
Endpoint domain: Mortality/survival
Primary endpoint: Re-Presentations to Any Emergency Department (ED)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Grade 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical status of patients at long-term follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % inhibition of Purinergic receptor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of glucose metabolism disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: local recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of Zometa retained in body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family and Provider/Teacher Relationship Quality (FTPRQ)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Teachers' Sense of Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Involvement Questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Activities with Your Child
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity and specificity of non-contrast MRA and VE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflow rate constant K1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Score on WHO Adult ADHD Self-Report Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in disease activity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Fetal AV heart block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of vaccine-related solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time From First Dose to Sustained Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time evolution of VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time evolution of gut hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Any Grade HFSR Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of vorinostat in combination with chemoradiation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximally tolerated dose of vorinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain report during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Grade 3 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of CTC/DTC in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of CTC/DTC in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of CTC/DTC in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of cfDNA in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantity of cfDNA in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantity of cfDNA in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in vivo viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of post-operative pain after 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snoring classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum miR-206 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sudomotor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day length of invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of PRNT50 to DENV-1, DENV-2, DENV-3, and DENV-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change of bilirubin metabolism in fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incremental areas under the curves of plasma glucose after meal challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintaining vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitigating pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of shock, internal bleeding, organ failure, or death
Endpoint domain: Mortality/survival
Primary endpoint: Technology acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Associative Memory Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Advanced oxidation protein product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drug cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of adverse events Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve of tenofovir concentration matrix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who consider the tenofovir study products acceptable for use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Confirmed Hematologic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Reintervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of successful conservative management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in 10-point visual analog scale of craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in Obsessive Compulsive Drug Use Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Premature Infant Pain Profile (PIPP) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroesophageal reflux symptoms in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Skeletal muscle strength and performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IL-26 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coronary catheterization without re-vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCt between SYP-1512 and Revlimid cap(25mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax between SYP-1512 and Revlimid cap(25mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited local reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of ambulatory appendectomy patients that have ambulatory surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of readmission of appendectomy patients that had ambulatory surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Misusing Metered-Dose Inhaler (MDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol dose required for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Telmisartan in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Telmisartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Interferon therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of postoperative quantitative TLU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and specificity of bioimpedance technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eadi-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h Holter reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First incidence of hand-foot syndrome (HFS) ≥ grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Hip Joint Internal and External Rotation Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between LensAge and chronological age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and Rate of Implant-Associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Implant Revision, Removal and Supplemental Fixation Procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Permanent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Attitudinal Preference Score of Psychotherapy over Antidepressants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hallucinogen Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of CTA to SPECT for the diagnosis of CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average 24 hour blood pressure less than 130/80 mmHg after 26 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in systolic 24 hour blood pressure after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of conducting pre-operative SLN mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of stereotactic vacuum assisted breast biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: renal allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Bladder outlet obstruction confirmation/exclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean difference of fractional anisotropy of the prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plaque stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in MEP signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of LLR (F-waves)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygenation of the paraspinal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients diagnosed with acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of all ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: 10-meter Walking Test (10mWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration of MNTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Troponin Ic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shoulder Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptions of school experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in moderate to vigorous physical activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mammogram receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apparent Diffusion Coefficients (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Signal-to-noise Ratio (SNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective measurement of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of total fetal birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stillbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neonatal birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Changes in Local Skin Reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Successful Follicular Engraftment of NB01
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Achieving Success on Investigator Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pupillary Reflex Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: regression motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in HDL-C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Passive Extension Deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance walked in the Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil to Lymphocyte Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: tolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in the FACT-Hep scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pathological response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants with any Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Time from first drug delivery to operator-perceived sufficient relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation difficulty using the intubation difficulty scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator satisfaction with intubating conditions using visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Failure rate of endotracheal intubation and requirement for alternative airway management methods
Endpoint domain: Adverse events/effects
Primary endpoint: Daily consumed fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily consumed whole grains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily consumed added sugars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality in septic shock patients
Endpoint domain: Mortality/survival
Primary endpoint: Changes in visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in temperature gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricle divided by left ventricular diameter (RV/LV ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Average Daily Pain Score (ADPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of ADHD/S-ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Naming Test (BNT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduction in duration of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative Stool H-Pylori-Ag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility of regimen defined as the number of participants who are successfully infused with T cell DLT and CIML NK cells
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Unexpected early mortality
Endpoint domain: Mortality/survival
Primary endpoint: Unacceptable GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of leukemia-free survival (LFS)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: Nicotine Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of atypical antipsychotic(s) during hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily dosage of atypical antipsychotic(s) during hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mode of administration of atypical antipsychotic(s) during hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Smoke-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline In Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Linkage rates of 11Craclopride in the nucleus accumbens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of All Study Participants Who Demonstrate a Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes